ARTICLE | Clinical News
Anturol meets overactive bladder endpoint
July 27, 2010 11:46 PM UTC
Antares Pharma Inc. (NYSE-A:AIS) said once-daily topical Anturol met the primary endpoint in a Phase III trial to treat overactive bladder (OAB). Both 56 and 84 mg doses of the advanced transdermal de...